🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Follicular Lymphoma (FL)

Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL NCT06151080Phase 21 site📍 Xiamen The First Affiliated Hospital of Xiamen University · Tests: Lenalidomide combined with G-CHOP (LO CHOP) A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL NCT05899621n/a1 site📍 Shanghai Ruijin Hospital · Tests: Obinutuzumab, Lenalidomide, Bendamustine, Cyclophosphamide, Doxorubicin Epco, Zanu, Ritux for R/R FL or MZL NCT06563596Phase 23 sites📍 Boston📍 New York📍 Columbus Reid Merryman, MD · Tests: Zanubrutinib, Rituximab, Epcoritamab Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy NCT05255354n/a1 site📍 Palo Alto Adaptive Biotechnologies · Tests: ClonoSEQ Odronextamab in Low Tumor Volume Advanced FL NCT07128641Phase 21 site📍 Boston Gottfried von Keudell, MD PhD · Tests: Odronextamab Long-term Follow up Local Registry Study of Kymriah in South Korea NCT06785818n/a18 sites📍 Bundang Gu📍 Seongnam-si📍 Gyeonggi-do Novartis Pharmaceuticals · Tests: Tisagenlecleucel Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma NCT07731789Phase 21 site📍 Seattle University of Washington · Tests: Rituximab, Tafasitamab, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies. NCT06542250Phase 1, Phase 231 sites📍 La Jolla📍 Boston📍 Rochester AstraZeneca · Tests: AZD5492 A Study of ARC-02 in B-cell NHL NCT07691606Phase 129 sites📍 Los Angeles📍 Louisville📍 New York Taiho Oncology, Inc. · Tests: ARC-02, Rituximab A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma NCT07562022Phase 31 site📍 Beijing Sinocelltech Ltd. · Tests: SCTB35 injection, Rituximab, Lenalidomide A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies NCT04830137Phase 116 sites📍 Duarte📍 Orange📍 San Francisco Nurix Therapeutics, Inc. · Tests: NX-2127 NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19) NCT07502118Phase 2, Phase 34 sites📍 Ankara📍 Ankara📍 Ankara Health Institutes of Turkey · Tests: Talikabtagene Autoleucel HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL NCT06792825Phase 21 site📍 Minneapolis Masonic Cancer Center, University of Minnesota · Tests: Tafasitamab, Rituximab, Lenalidomide Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL) NCT04989621Phase 23 sites📍 Guangzhou📍 Guangzhou📍 Guangzhou Sun Yat-sen University · Tests: Orelabrutinib and Rituximab, Orelabrutinib Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms NCT06043011n/a1 site📍 Freiburg im Breisgau iOMEDICO AG · Tests: Routine care as per site standard. Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma NCT07249905Phase 1, Phase 26 sites📍 Richmond📍 Nedlands📍 Haifa ModeX Therapeutics, An OPKO Health Company · Tests: MDX2003 Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL) NCT07750886n/a1 site📍 Austin Natera, Inc. Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader NCT05294731Phase 1, Phase 229 sites📍 Bengbu📍 Hefei📍 Beijing BeOne Medicines · Tests: Tacabrutideg MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL) NCT04110301Phase 1, Phase 21 site📍 Beijing Beijing Mabworks Biotech Co., Ltd. · Tests: Recombinant Humanized Monoclonal Antibody MIL62 Injection, Lenalidomide A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies NCT07609862Phase 1, Phase 21 site📍 Tianjin Guangzhou Lupeng Pharmaceutical Company LTD. · Tests: Lacutoclax+Rocbrutinib REal World Data in LYmphoma and Survival in Adults NCT03869619n/a37 sites📍 Arras📍 Besançon📍 Bordeaux Hospices Civils de Lyon · Tests: Real-life epidemiological platform of lymphoma in France Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial NCT05816850n/a26 sites📍 Alessandria📍 Biella📍 Brescia Fondazione Italiana Linfomi - ETS · Tests: EZH2 mutations/CNAs by droplet digital PCR (ddPCR), EZH2-derived gene expression signature by RNA-Seq Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma NCT06553352Phase 21 site📍 Xiamen The First Affiliated Hospital of Xiamen University · Tests: Zanubrutinib combined with Obinutuzumab A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma NCT06091254Phase 3190 sites📍 Tucson📍 Los Angeles📍 Orange Regeneron Pharmaceuticals · Tests: Odronextamab, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial NCT06948786Phase 21 site📍 Seattle University of Washington · Tests: Pirtobrutinib, Mosunetuzumab, Biospecimen Collection, Biopsy Procedure, Computed Tomography Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma NCT06830759n/a73 sites📍 Ciudad Autonoma de Buenos Aire📍 Pilar📍 Ciudad Autonoma de Buenos Aire AbbVie A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma NCT07548697EARLY Phase 11 site📍 Wuhan Union Hospital, Tongji Medical College, Huazhong University… · Tests: CT1182 injection Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL NCT06526793Phase 294 sites📍 Phoenix📍 Duarte📍 Jacksonville AstraZeneca · Tests: Surovatamig A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies NCT05780034Phase 19 sites📍 Denver📍 Sarasota📍 Chapel Hill Accutar Biotechnology Inc · Tests: AC676 Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study NCT05846763n/a1 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy